Our Company / Ethics&transparency / Patients associations

Supporting
patient groups

Over the course of the years, Alfasigma has established collaborative relationships with
numerous patients associations – non-profit organisations that have made offering better assistance to patients and tangible support to caregivers their mission. Through this collaboration, Alfasigma has positioned itself to understand the priorities and needs of patients and help organisations spread information about disease, drug and treatment.
These associations are supported through donations or sponsorship programmes and activities that share common goals: promoting the spread of knowledge on specific disorders, stimulate research and protect the right to health.
In compliance with its Code of Ethics and principles of transparency, Alfasigma periodically publishes and updates the list of patient associations it has supported. 

By June 30 of the following year, Alfasigma publishes transfers of value to patient associations in its Transparency Report (under “Healthcare professionals and healthcare organizations – Our company / Ethics and transparency / Healthcare professionals and healthcare organizations”) and discloses the following information in this section:

  • A list of Patients' Associations with which service contracts were concluded in the previous year;

  • A list of Patients' Associations supported in the previous year, including the purposes of the support and the economic value of the funding provided to each association;

  • A list of transfers of value to expert patients, containing the names of the individuals involved (subject to specific consent), along with the total amount of transfers of value made.

Read More

Social contract between the company and internal and external stakeholders having a normative value for the entire Alfasigma system.

Corporate Social Responsibility (CSR) is part of our company's DNA and constitutes one of its distinctive characteristics.

Reporting an adverse event is important in order to safeguard the patients who are taking it and ensure a favourable benefit-risk balance for the population.
×

You’re entering Alfasigma global website

I agree